factor VIII

DRUG4 trials

Sponsors

Novo Nordisk A/S, Baxalta now part of Shire, Swedish Orphan Biovitrum, Universitair Medisch Centrum Utrecht

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With InhibitorsHemophilia Ableeding disorder coagulation disorder

Phase 4

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

CompletedNCT01561391

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Start: 1998-04-30End: 2004-05-31Updated: 2023-12-29

Unknown Phase

GAS-Hem Feasibility Study

CompletedNCT02674997

Baxalta now part of ShireHemophilia A

Start: 2016-08-05End: 2016-11-02Updated: 2021-03-17

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

CompletedNCT02976753

Swedish Orphan BiovitrumHemophilia A

Start: 2016-12-31End: 2021-11-03Updated: 2024-10-02

I-SWITCH: Changes in Immune profiles after SWITCH to a different factor VIII product

Active, not recruitingNL-OMON46126

Universitair Medisch Centrum Utrechtbleeding disorder coagulation disorder

Start: 2017-09-20Target: 150Updated: 2024-02-28

Related Papers

A-SURE: intra-patient comparison of prophylactic effectiveness of a recombinant factor VIII Fc fusion protein versus standard half-life factor VIII in hemophilia A

Hematology2025-07-04

Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study

BMJ Open2019-05-0110 citations